PHAXIAM Therapeutics
Created in 2004
Up & running (A)
Existing signals show a regular activitySocial networks
1,381 19,885 19,885Activities
Technologies
Entity types
Location
Bioserra 1, 60 Av. Rockefeller Bâtiment B, 69008 Lyon, France
Lyon
France
Employees
Scale: 51-200
Estimated: 84
SIREN
479560013Engaged catalyst
21
0 0Added in Motherbase
6 years, 7 months ago
Value proposition
Creating a global leader in extended phage therapies
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Biotechnology, phage, innovation, bacterial infection, viruses, staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, and phxmOriginal language
Créer un leader mondial de la phagothérapie étendue
PHAXIAM est une société biopharmaceutique qui développe des traitements innovants contre les infections bactériennes résistantes, responsables de nombreuses infections graves. La société s'appuie sur une approche innovante basée sur l'utilisation de phages, des virus naturels tueurs de bactéries. PHAXIAM développe un portefeuille de phages ciblant 3 des bactéries les plus résistantes et les plus dangereuses, qui représentent à elles seules plus des deux tiers des infections nosocomiales résistantes : Staphylococcus aureus, Escherichia coli et Pseudomonas aeruginosa.
PHAXIAM est cotée sur le Nasdaq Capital Market aux Etats-Unis (ticker : PHXM) et sur le marché réglementé d'Euronext à Paris (code ISIN : FR0011471135, ticker : PHXM). PHAXIAM fait partie des indices CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 et Next Biotech.
Phaxiam
https://phaxiam.com/en/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Institut Carnot CALYM | Other 18 Jan 2023 | | |
 Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Other 13 Dec 2024 | | |
 Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Other 20 Dec 2024 | | |
 Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix (APHP) Health, Medical Practices | Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix (APHP) Health, Medical Practices | Other 20 Dec 2024 | | |
 Onisep National and local authorities, Government Administration | Onisep National and local authorities, Government Administration | Other 13 Dec 2024 | | |
 bioMérieux Biotechnology, Biotechnology Research | bioMérieux Biotechnology, Biotechnology Research | Other 22 Nov 2024 | | |
 La Tribune Media, Newspapers | La Tribune Media, Newspapers | Other 19 Sep 2024 | | |
 | ANSM Agence nationale de sécurité du médicament et des produits de santé | Other 20 Dec 2024 | | |
 | Haute Autorité de Santé | Other 31 Dec 2023 | | |
 | Ministère de la Santé | Other 31 Dec 2023 | | |